Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medeze NK
- Development stage
- Preclinical
- Lead developer
- Medeze
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Medeze NK is an autologous natural killer (NK) cell immunotherapy developed by the MEDEZE GROUP. The therapy utilizes the **Osaki Method**, a proprietary feeder-free expansion protocol originally developed by Dr. Junichi Masuyama at the New City Osaki Clinic in Japan. This method involves culturing a patient's NK cells in a patented closed-system using specialized media and environmental controls to produce large quantities of highly activated NK cells. These cells are then reinfused into the patient to enhance the body's innate immune response against pathogens and malignant cells. The program includes both immune profiling (via the Masuyama Test) and the expansion and storage of NK cells for future oncological or general immunotherapy use.
- Brand names
- Medeze NK
- Other names
- Highly Active NK Cell TherapyNK cell immunotherapyMEDEZE NK cell therapy
Beyond the preview
Go deeper on Medeze NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medeze NK.